Transcranial Electrical Stimulation for Cervical Dystonia

NCT ID: NCT03369613

Last Updated: 2022-04-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-10-27

Study Completion Date

2021-09-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There are two phases.

Phase I: A single visit which includes a screening, clinical scales, and a MRI scan with simultaneous tES/sham tES in a randomized block design. Enrolls both Cervical Dystonia (CD) patients and healthy controls.

Phase II: 5 consecutive days of 30-90 min visits to campus for tES or sham tES. Transcranial magnetic stimulation (TMS) measures and clinical scales will also be included on Day 1 and Day 5 visits. Enrolls only CD patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Phase I:

Enrolls both CD patients and healthy controls.

One approximately 3 hour visit which includes:

* a screening \& neurological exam,
* clinical scales \& questionnaires,
* a (approx.) 60 min MRI scan with simultaneous tES/sham tES in a randomized block design and EMG

Phase II:

Enrolls only CD patients.

Five consecutive days of study visits.

Day 1:

* TMS screening,
* repeated neurological assessment and clinical scales if \>1 month since MRI visit
* 30 min TMS session with concurrent EMG
* 20 min tES or sham tES session

Days 2-4:

\- 20 min tES or sham tES session

Day 5:

* 20 min tES or sham tES session
* 30 min TMS session with concurrent EMG
* repeated neurological assessment and clinical scales

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Cervical Dystonia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MRI - HC tDCS

Healthy controls in Phase 1 transcranial electrical stimulation set to direct current

Group Type ACTIVE_COMPARATOR

transcranial electrical stimulation

Intervention Type DEVICE

The device is a Neoprene headcap that holds an array of padded electrodes close to the scalp to stimulate the underlying brain.

MRI - HC tACS

Healthy controls in Phase 1- transcranial electrical stimulation set to alternating current

Group Type ACTIVE_COMPARATOR

transcranial electrical stimulation

Intervention Type DEVICE

The device is a Neoprene headcap that holds an array of padded electrodes close to the scalp to stimulate the underlying brain.

MRI - CD tCDS

Cervical dystonia in Phase 1 transcranial electrical stimulation set to direct current

Group Type ACTIVE_COMPARATOR

transcranial electrical stimulation

Intervention Type DEVICE

The device is a Neoprene headcap that holds an array of padded electrodes close to the scalp to stimulate the underlying brain.

MRI - CD tACS

Cervical dystonia in Phase 1 transcranial electrical stimulation set to alternating current

Group Type ACTIVE_COMPARATOR

transcranial electrical stimulation

Intervention Type DEVICE

The device is a Neoprene headcap that holds an array of padded electrodes close to the scalp to stimulate the underlying brain.

Phase II - Stim

Cervical dystonia in Phase 2 transcranial electrical stimulation setting is active

Group Type ACTIVE_COMPARATOR

transcranial electrical stimulation

Intervention Type DEVICE

The device is a Neoprene headcap that holds an array of padded electrodes close to the scalp to stimulate the underlying brain.

Phase II - Sham

Cervical dystonia in Phase 2 transcranial electrical stimulation setting is sham

Group Type SHAM_COMPARATOR

transcranial electrical stimulation

Intervention Type DEVICE

The device is a Neoprene headcap that holds an array of padded electrodes close to the scalp to stimulate the underlying brain.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

transcranial electrical stimulation

The device is a Neoprene headcap that holds an array of padded electrodes close to the scalp to stimulate the underlying brain.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Right-handed
* On a stable dose of all medications used to treat dystonia for the month previous to enrollment
* No botox injections in the 10 weeks previous to enrollment


\- Right-handed

Exclusion Criteria

* Any contraindication to MRI scanning, tES, or TMS (e.g pregnancy, history of seizures, significant systemic medical conditions, untreated psychiatric or neurological conditions)
* Evidence on neurological exam of any potentially confounding neurological disorder
* Evidence of significant cognitive impairment
* Patients with dystonia symptoms beginning prior to the age of 18 will be excluded
* Patients with secondary dystonia resulting from medications or that are part of another neurological disorder (e.g. Parkinson's disease) will be excluded
* Medication that might predispose the subject to seizures

Healthy Controls


* Any contraindication to MRI scanning, tES, or TMS (e.g pregnancy, history of seizures, significant systemic medical conditions, untreated psychiatric or neurological conditions)
* Evidence on neurological exam of any potentially confounding neurological disorder
* Evidence of significant cognitive impairment
* Medication that might predispose the subject to seizures
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Colorado, Denver

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Brian Berman, MD

Role: PRINCIPAL_INVESTIGATOR

University of Colorado, Denver

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Colorado Denver

Aurora, Colorado, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

17-1322

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.